Alps Group Inc(ALPS)

Biotechnology · Kuala Lumpur, WP

$0.38-0.02 (-5.00%)

Delayed quote: Oct 6, 2026, 9:35 AM EDT

Alps Group (ALPS) Price/Book Ratio: History & Chart | TGMCharts

PB Ratio: N/A

Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.

The P/B ratio is N/A as of 2026-10-06T13:35:27.341Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:35:27.341Z.

Quote observation: 2026-10-06T13:35:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 63,232,125
Total stockholders equity · period ending 2026-03-31: N/A
Preferred stock · period ending 2026-03-31: N/A
Book value attributable to common shareholders · period ending 2026-03-31: N/A

FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f

P/E Ratio|ROE|Debt to Equity|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALPS PB Ratio Metrics

PB RATIO

N/A

ALPS Competitors' PB Ratio

ALPS

Alps Group Inc

Current

Market Cap

$63.23M

PB Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs ALPS

Market Cap

$64.31M

PB Ratio

N/A

TTM Avg

5.95

3Y Avg

4.54

5Y Avg

4.16

GOSS

Gossamer Bio, Inc.

vs ALPS

Market Cap

$65.69M

PB Ratio

N/A

TTM Avg

5.15

3Y Avg

6.79

5Y Avg

5.08

CING

Cingulate Inc.

vs ALPS

Market Cap

$64.11M

PB Ratio

2.73

TTM Avg

5.65

3Y Avg

4.13

5Y Avg

250.85

KLRS

Kalaris Therapeutics Inc

vs ALPS

Market Cap

$63.30M

PB Ratio

1.10

TTM Avg

2.15

3Y Avg

6.77

5Y Avg

28.55

INCR

InterCure Ltd.

vs ALPS

Market Cap

$62.78M

PB Ratio

0.50

TTM Avg

0.43

3Y Avg

0.63

5Y Avg

0.94

ACET

Adicet Bio, Inc.

vs ALPS

Market Cap

$60.44M

PB Ratio

0.50

TTM Avg

0.53

3Y Avg

0.47

5Y Avg

0.88

CSBR

Champions Oncology, Inc.

vs ALPS

Market Cap

$68.91M

PB Ratio

17.70

TTM Avg

21.25

3Y Avg

131.92

5Y Avg

75.65

FBIO

Fortress Biotech, Inc.

vs ALPS

Market Cap

$70.09M

PB Ratio

0.43

TTM Avg

1.39

3Y Avg

1.48

5Y Avg

1.46

INKT

MiNK Therapeutics, Inc.

vs ALPS

Market Cap

$60.33M

PB Ratio

N/A

TTM Avg

6.85

3Y Avg

6.82

5Y Avg

6.82

NAME	MARKET CAP	PB RATIO	TTM	3Y	5Y
Alps Group Inc (ALPS)	$63.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$64.31M	N/A	5.95	4.54	4.16
Gossamer Bio, Inc. (GOSS)vs ›	$65.69M	N/A	5.15	6.79	5.08
Cingulate Inc. (CING)vs ›	$64.11M	2.73	5.65	4.13	250.85
Kalaris Therapeutics Inc (KLRS)vs ›	$63.30M	1.10	2.15	6.77	28.55
InterCure Ltd. (INCR)vs ›	$62.78M	0.50	0.43	0.63	0.94
Adicet Bio, Inc. (ACET)vs ›	$60.44M	0.50	0.53	0.47	0.88
Champions Oncology, Inc. (CSBR)vs ›	$68.91M	17.70	21.25	131.92	75.65
Fortress Biotech, Inc. (FBIO)vs ›	$70.09M	0.43	1.39	1.48	1.46
MiNK Therapeutics, Inc. (INKT)vs ›	$60.33M	N/A	6.85	6.82	6.82

Book Value Analysis

P/B Ratio

N/A

Market Price / Book Value per Share

PB Ratio Formula & Definition

PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)

The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PB Ratio: N/A

ALPS PB Ratio Metrics

ALPS Competitors' PB Ratio

Book Value Analysis

PB Ratio Formula & Definition

Related Metrics